Atara Biotherapeutics (ATRA) Free Cash Flow (2013 - 2026)

Atara Biotherapeutics has reported Free Cash Flow for 14 years, with the latest figure at -$3.1 million in Q1 2026.

• For the quarter ending Q1 2026, Free Cash Flow rose 89.08% year-over-year to -$3.1 million; the trailing twelve-month figure through Mar 2026 stood at -$25.9 million (up 61.59% YoY), and the FY2025 full-year result was -$50.9 million, up 26.13% from the prior year.
• Free Cash Flow for Q1 2026 stood at -$3.1 million, up from -$5.7 million in the prior quarter.
• The five-year high for Free Cash Flow was -$3.1 million in Q1 2026, with the low at -$85.7 million in Q1 2022.
• Historically, Free Cash Flow has averaged -$34.5 million across 5 years, with a median of -$29.7 million in 2024.
• Annual changes were most pronounced in 2024 — Free Cash Flow jumped 92.22% — and 2025, when it sank 145.35%.
• Atara Biotherapeutics' Free Cash Flow stood at -$56.9 million in 2022, then grew by 11.23% to -$50.5 million in 2023, then soared by 51.38% to -$24.6 million in 2024, then surged by 76.8% to -$5.7 million in 2025, then jumped by 46.06% to -$3.1 million in 2026.
• The last three Free Cash Flow figures came in at -$3.1 million (Q1 2026), -$5.7 million (Q4 2025), and -$9.8 million (Q3 2025), per Business Quant data.